Handelsbanken Fonder
APLS

Handelsbanken Fonder’s Apellis Pharmaceuticals APLS Stock Holding History

Handelsbanken Fonder’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,400
Closed -$1.42M – 1493
2026
Q1 		$1.42M Hold
35,400
– – ﹤0.01% 880
2025
Q4 		$889K Sell
35,400
-3,700
-9% -$86.8K ﹤0.01% 1087
2025
Q3 		$885K Buy
39,100
+8,900
+29% +$208K ﹤0.01% 1057
2025
Q2 		$523K Sell
30,200
-400
-1% -$7.4K ﹤0.01% 1226
2025
Q1 		$669K Hold
30,600
– – ﹤0.01% 1124
2024
Q4 		$976K Buy
30,600
+3,000
+11% +$90.2K ﹤0.01% 978
2024
Q3 		$796K Buy
27,600
+3,700
+15% +$137K ﹤0.01% 1037
2024
Q2 		$917K Buy
23,900
+1,500
+7% +$67.9K ﹤0.01% 876
2024
Q1 		$1.32M Sell
22,400
-200
-0.9% -$12.7K 0.01% 737
2023
Q4 		$1.35M Buy
22,600
+5,400
+31% +$274K 0.01% 684
2023
Q3 		$654K Hold
17,200
– – ﹤0.01% 923
2023
Q2 		$1.57M Buy
17,200
+2,200
+15% +$190K 0.01% 596
2023
Q1 		$989K Buy
15,000
+3,000
+25% +$173K 0.01% 696
2022
Q4 		$621K Buy
12,000
+300
+3% +$15.9K ﹤0.01% 843
2022
Q3 		$799K Hold
11,700
– – 0.01% 733
2022
Q2 		$529K Sell
11,700
-1,700
-13% -$77.5K ﹤0.01% 993
2022
Q1 		$681K Hold
13,400
– – ﹤0.01% 988
2021
Q4 		$634K Hold
13,400
– – ﹤0.01% 1187
2021
Q3 		$442K Hold
13,400
– – ﹤0.01% 1429
2021
Q2 		$847K Buy
13,400
+600
+5% +$31K ﹤0.01% 1017
2021
Q1 		$549K Hold
12,800
– – ﹤0.01% 1150
2020
Q4 		$732K Hold
12,800
– – ﹤0.01% 962
2020
Q3 		$386K Hold
12,800
– – ﹤0.01% 1124
2020
Q2 		$418K Buy
+12,800
New +$411K ﹤0.01% 1042

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Handelsbanken Fonder's APLS Position: Q2 2026 in Review

Handelsbanken Fonder sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 35,400 shares — an estimated $1.42M sold.

Handelsbanken Fonder first reported a position in APLS in Q2 2020 and held it in 24 quarters. The position peaked at $1.57M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Handelsbanken Fonder reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Handelsbanken Fonder sold 35,400 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Handelsbanken Fonder first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 24 quarters.
  • Handelsbanken Fonder's Apellis Pharmaceuticals position peaked at $1.57M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.